Loan terms

INOVIQ (ASX:IIQ) Obtains SubB2M US Patent for Diagnostics Applications – The Market Herald

Subscribe

Be the first with news that moves the market

  • INOVIQ (IIQ) Receives U.S. Patent Covering its SubB2M Technology and Providing U.S. Intellectual Property Protection for Diagnostic Applications
  • The patent is titled “Subtilase cytotoxin B subunit mutant” and was issued to Griffith University and the University of Adelaide
  • SubB2M technology is based on a modified protein that specifically detects the pan-cancer biomarker Neu5Gc found in several human cancers
  • CEO Dr. Leearne Hinch says the grant is a significant achievement for the company, as the United States is the first market where SubB2M tests are commercialized as lab-developed tests.
  • INOVIQ shares are up 14.1%, trading at 44.5 cents as of 10:45 a.m. AEST

INOVIQ (IIQ) has been granted a US patent that covers its SubB2M technology and provides intellectual property protection in the United States for diagnostic applications.

The SubB2M technology is based on a modified protein that specifically detects the pan-cancer biomarker Neu5Gc which is found in multiple human cancers including breast, ovarian and prostate.

The patent is titled “Subtilase cytotoxin B subunit mutant” and was issued to Griffith University and the University of Adelaide.

It expires on July 9, 2038 and claims modified SubB proteins capable of binding N-glycolylneuraminic acid (Neu5Gc) and its variants and fragments, such as SubB2M.

The US grant follows the company that receives an Australian grant for the same protection.

CEO Dr. Leearne Hinch said the award is a significant achievement for the company, as the United States is the first market where SubB2M tests are commercialized as lab-developed tests.

“INOVIQ has made solid progress on the SubB2M program and we are pleased to report that the performance of the SubB2M-CA15.3 assay for the detection of breast cancer has been successfully replicated by ResearchDx,” she said. .

“The assay is currently undergoing optimization and validation before moving into clinical trials for breast cancer surveillance. This is an exciting step forward for the SubB2M
diagnostic program.

Inoviq shares were up 14.1%, trading at 44.5 cents at 10:45 a.m. AEST.